Related Experiment Video
Updated: Jun 20, 2026

06:43
Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
Published on: April 3, 2026
Imaging of gastrointestinal stromal tumors before and after imatinib mesylate therapy
S Shankar1, S K Dundamadappa, A R Karam
1Radiology Department, University of Massachusetts Medical Center, Worcester, Massachusetts 01655, USA.
Acta Radiologica (Stockholm, Sweden : 1987)
|September 8, 2009
Abstract:
Gastrointestinal stromal tumors (GISTs) account for the majority of gastrointestinal mesenchymal tumors. Recent advances in treatment using the molecular targeting agent imatinib mesylate have shown startling response rates and variegated imaging findings. We present the various imaging appearances of GIST on computed tomography (CT) and magnetic resonance imaging (MRI), both before and after treatment.
